CN112014372A - Method for quickly, qualitatively and quantitatively evaluating action effects of different antibacterial drugs - Google Patents
Method for quickly, qualitatively and quantitatively evaluating action effects of different antibacterial drugs Download PDFInfo
- Publication number
- CN112014372A CN112014372A CN202010815660.0A CN202010815660A CN112014372A CN 112014372 A CN112014372 A CN 112014372A CN 202010815660 A CN202010815660 A CN 202010815660A CN 112014372 A CN112014372 A CN 112014372A
- Authority
- CN
- China
- Prior art keywords
- drug
- different
- ratio
- detected
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000000694 effects Effects 0.000 title claims abstract description 30
- 230000009471 action Effects 0.000 title claims abstract description 18
- 229940124350 antibacterial drug Drugs 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 89
- 229940079593 drug Drugs 0.000 claims abstract description 86
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims abstract description 54
- 238000001237 Raman spectrum Methods 0.000 claims abstract description 32
- 230000002503 metabolic effect Effects 0.000 claims abstract description 22
- 241000894006 Bacteria Species 0.000 claims abstract description 19
- 230000035945 sensitivity Effects 0.000 claims abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 9
- 238000012258 culturing Methods 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 14
- 230000008859 change Effects 0.000 claims description 11
- 238000004364 calculation method Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 79
- 238000001069 Raman spectroscopy Methods 0.000 abstract description 19
- 238000005516 engineering process Methods 0.000 abstract description 13
- 238000012216 screening Methods 0.000 abstract description 6
- 238000002372 labelling Methods 0.000 abstract description 3
- 210000004962 mammalian cell Anatomy 0.000 abstract description 3
- 238000007877 drug screening Methods 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 70
- 235000013024 sodium fluoride Nutrition 0.000 description 34
- 239000011775 sodium fluoride Substances 0.000 description 34
- 241001521783 Streptococcus mutans UA159 Species 0.000 description 25
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 20
- 229960003260 chlorhexidine Drugs 0.000 description 20
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 230000010261 cell growth Effects 0.000 description 9
- 238000009630 liquid culture Methods 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 241000194019 Streptococcus mutans Species 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000003841 Raman measurement Methods 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000003068 static effect Effects 0.000 description 5
- 206010061819 Disease recurrence Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910001634 calcium fluoride Inorganic materials 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000003390 bioluminescence detection Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
The invention relates to the technical field of drug screening, in particular to a method for screening a drug by using heavy water (D)2O) labeling and combining with living single cell Raman spectroscopy technology to quickly and quantitatively evaluate different antibacterial drugs. The method comprises the steps of culturing anti-bacteria by using heavy water markers and a drug to be detected, respectively obtaining single-cell Raman spectra at different time points in a culture period, generating Raman spectra of C-D peaks with different heights due to different metabolic activities of cells under different drugs to be detected and different concentrations of the drugs to be detected, and judging the sensitivity of the drug to be detected according to the Raman spectra, thereby identifying the action effect of the drug. The living single cell Raman spectrum technology adopted by the invention can be used for evaluating and screening the drugs causing different metabolic inhibition degrees to the target cells by combining the heavy water marking technology, and can evaluate the drug action level on the time axis span, thereby having universality in the fields of bacteria, mammalian cells and the like and having wide application prospect.
Description
Technical Field
The invention relates to the technical field of drug screening, in particular to a method for screening a drug by using heavy water (D)2O) labeling and combining with living single cell Raman spectroscopy technology to quickly and quantitatively evaluate the action effects of different antibacterial drugs.
Background
With the increasing popularity of antibacterial drugs including antibiotics and the like, the problems of antibiotic abuse and bacterial resistance have become increasingly apparent, and the emergence of bacteria resistant to most commonly used antibiotics in severe infections has made the situation of no drug available a major global health safety issue faced in the 21 st century. Conventional evaluation criteria for antimicrobial agents are divided into cell growth-based means and non-cell growth-based means. Among the drug evaluation systems based on cell growth include agar diffusion method, thin-layer chromatography biological self-development, gradient dilution method, etc., which depend on cell division and proliferation, and therefore, usually take a long time (usually more than 16h) to complete. Meanwhile, the Minimum Inhibitory Concentration (MIC) is taken as a judgment index, which is defined as the concentration of the drug when the cells are not obviously grown after being exposed to the drug for 18-24h, but the cells do not grow normally and do not represent cell death, so that the method can only judge the inhibitory effect of the cells but not the bactericidal effect of the drug.
Since environmental bacteria exist in a non-growing but still metabolically active (NGMA) state, bacteria in this state cannot be identified by the above cell growth-based methods, but they play a critical role in the later disease recurrence process and are the subject of major concern. Therefore, methods relying solely on growth are still largely lacking in the evaluation of the effect of drugs.
On the other hand, the drug evaluation system not based on cell growth mainly comprises technologies of determining the integrity of cell membranes by ATP bioluminescence detection and dyeing with fluorochromes such as Propidium Iodide (PI), and the like, and saves time compared with the former technology because cell proliferation is not relied on, but because the action mechanisms of drugs are different, the change trend of internal ATP is caused, the destructiveness of cell membranes is obviously different, and even the opposite conclusion is produced, so the judgment of the method sometimes has errors. In addition, the method is based on the research of cells at the population level, so that the heterogeneity among the cells is ignored, and the problems of cell drug resistance and the like cannot be comprehensively evaluated. In view of the above, the development of novel antibacterial agents, including novel antibiotics, and means and criteria for rapidly evaluating the effects of drugs are becoming of great importance.
The single cell Raman technology is increasingly becoming an important means for measuring cell phenotype due to its characteristics of simplicity, rapidness, no need of marking, capability of providing rich cell component information and the like. By observing the change of macromolecular substances in cells, the Single Cell Raman Spectrum (SCRS) can be used for distinguishing cell types and growth states, identifying product accumulation and the like. Recently, a new approach based on raman spectroscopy (raman) has been proposed and applied to determine the effect of external stimuli including drugs on cell phenotype at the single cell level (Teng, l.; Wang, x.; Gou, h.; Ren, l.; Wang, t.; Wang, y.; Ji, y.; Huang, w.e.; Xu, j., Label-free, rapid and qualitative phenotyping of stress response in e.coli viman raman 2016,6, 34359). The method is based on the statistical analysis of the full spectrum of the cell fingerprint area, and judges the response of the cell to the external stimulus by observing the change of the special Raman peak position, thereby evaluating the action mechanism of the stimulus to a certain extent. However, due to the weak change of the components in the cells and the sensitivity of the raman spectrum to other factors such as cell types, cell growth states, and test environments, the analysis process becomes complicated and is not suitable for all microorganisms, and even not applicable to non-culturable microorganisms. Therefore, a clearer universal mark needs to be found for evaluating the drug action, so as to obtain a method for rapidly and quantitatively evaluating the action effects of different antibacterial drugs and screening drug-resistant bacteria.
Disclosure of Invention
The invention aims to provide a method for quickly, qualitatively and quantitatively evaluating the action effects of different antibacterial drugs.
In order to achieve the purpose, the invention adopts the technical scheme that:
a method for quickly, qualitatively and quantitatively evaluating the action effect of different antibacterial drugs includes such steps as using heavy water label and the drug to be tested to culture antibacterial bacteria, respectively obtaining the Raman spectra of single cells at different time points in culture period, generating the Raman spectra of C-D peaks with different heights by the metabolic activities of cells under different drugs and concentrations of drugs, and judging the sensitivity of the drug to be tested according to the Raman spectra.
Adding the anti-bacteria into different drugs to be detected, comparing the generation speed of the C-D peak of the cell under different drugs to be detected with a control without the drugs, and judging the sensitivity to the drugs.
The heavy water mark and the drug to be detected are utilized to culture the anti-germ, and the C-D peak (1800 ion 2500 cm) of the single cell in the culture is detected by Raman spectrum under a period of time-1) Changed and then passed through the C-D peak (1800--1) And (3) obtaining the C-D-ratio of a single cell by change calculation, obtaining the delta C-D-ratios at different time points by the C-D-ratio, and further obtaining the minimum inhibitory metabolic concentration MIC-MA of the drug to be detected, namely quantitatively judging the sensitivity of the drug to be detected.
The C-D-ratio is C-D/(C-D + C-H), wherein C-D is a C-D peak (1800 ion 2500 cm)-1) Area, C-H is C-H peak (2600-3300 cm)-1) Area;
the Δ C-D-ratio is subtracted from the average of 0h of C-D-ratio over each time point;
the minimum inhibitory metabolic concentration MIC-MA is the minimum drug concentration at which the median Δ C-D-ratio of the cells is below 0 after several hours of drug exposure.
And respectively acquiring the SCRS of the culture solution single cells at different time points in the culture period, and generating Raman spectra containing C-D peaks with different heights by utilizing different metabolic activities of the cells under different drugs to be detected and different concentrations of the drugs to be detected so as to judge the sensitivity of the drugs to be detected.
Culturing the disease-resistant bacteria in the stage of culturing to a culture medium containing the heavy water marker and the drug to be detected under different concentrations, respectively taking culture solution cells at different time points in the culture period and collecting the single-cell Raman spectrum, wherein the time for collecting the Raman spectrum is 0.01-100s under the laser with the energy of 1-100 mW.
The drug to be detected at the different concentrations is a gradient from below the minimum inhibitory concentration to a concentration above the minimum inhibitory concentration.
Specifically, cells of a pathogen (such as common bacteria in the oral cavity, specifically Streptococcus mutans UA159) cultured overnight to a stationary phase are diluted to a volume ratio of 1:10 in a fresh culture medium (such as brain heart infusion Broth (BHI) culture medium) containing different concentrations of a drug to be detected and 30% of heavy water, and are cultured for 8 hours, and samples are respectively taken at 0,0.5,1,1.5,2,3,4,6 and 8 hours for raman measurement and SCRS are collected. The variation trend of the C-D peak, including the rising start time, the saturation height and the like of the C-D peak can be used for analyzing the response of cells to the medicine, so that the action effect and the mechanism of the medicine can be judged. Specifically, under the condition that a control group has no drug stimulation, the C-D peak rapidly rises and then enters a logarithmic growth period, and after reaching a certain height, the height of the C-D peak becomes stable and saturated and enters a plateau period; under the stimulation condition of the low-concentration medicament, the C-D peak does not appear in a period of time at the beginning of stimulation, then the C-D peak slowly rises, and finally the C-D peak is stabilized after reaching a relatively low saturation level; under the condition of high-concentration drug stimulation, no C-D peak or only extremely low C-D peak formation is observed in the observation time range.
The Streptococcus mutans UA159 is a common strain in an oral cavity, and is detected to have obvious C-D peak in the SCRS under the condition of existence of heavy water according to the mode, and the saturated C-D ratio is different along with different concentrations of the heavy water, and the Streptococcus mutans UA and the heavy water are in linear correlation relationship.
The drugs for detecting common bacteria in the oral cavity include, but are not limited to, sodium fluoride (NaF), Chlorhexidine (CHX), and ampicillin (Amp).
(some procedures for screening drug-resistant bacteria are given here)
The invention has the following function principle: in the presence of heavy water, the cells with metabolic activity can take up the heavy water for synthesizing internal macromolecules to carry out life activities, so that the C-H peak (2600--1) Drift, new C-D peak (1800 + 2500 cm)-1). Drift speed can reflect the synthesis speed of cell macromolecules for the same speciesThe cells can then characterize changes in their metabolic activity.
Therefore, the target cells are exposed in different drug environments, and the sensitivity of the target cells to the drugs can be judged by comparing the generation speed of the C-D peak with that of a control without the drugs, so that the effect of the drugs is identified, and the action mechanism of the drugs is analyzed to a certain extent.
The invention has the advantages that: simple, rapid, low cost, based on metabolic activity and can reflect cellular heterogeneity at the single cell level. Firstly, the method is independent of cell proliferation, so that the time required is shorter than that of the traditional growth-based method, and the difference can be seen within 0.5 h; secondly, the method reflects the activity of cells, so that bacteria which do not grow but have activity can be identified, thereby giving more appropriate drug concentration and having important significance for subsequent disease recurrence control; in addition, the method can comprehensively detect the drug sensitivity of the cells at the single cell level, thereby discovering the heterogeneity phenomenon which cannot be observed at the population level and providing more comprehensive basis for understanding the drug resistance mechanism of the cells and controlling diseases.
Drawings
FIG. 1 is a graph of the C-D-ratio of S.mutans UA159 over time in the presence of different concentrations of NaF according to an embodiment of the invention;
FIG. 2 is a graph showing the Δ C-D-ratio distribution of S.mutans UA159 at various concentrations of NaF exposed for 8 hours according to an embodiment of the present invention;
FIG. 3 is a graph showing the variation of C-D-ratio of S.mutans UA159 over time in the presence of different concentrations of CHX according to an embodiment of the present invention;
FIG. 4 is a graph showing the Δ C-D-ratio distribution of S.mutans UA159 at different concentrations of CHX for 8h according to an embodiment of the present invention;
FIG. 5 is a graph of the C-D-ratio of S.mutans UA159 over time in the presence of various concentrations of Amp, according to an embodiment of the invention;
FIG. 6 is a distribution of Δ C-D-ratios of S.mutans UA159 at different concentrations of Amp exposed for 8h according to an embodiment of the invention;
FIG. 7 shows that S.mutans UA159 and S.mutans C180-2FR provided for embodiments of the invention respond differently in the presence of different concentrations of NaF.
Detailed Description
The method comprises the steps of firstly adding activated microbial cells into a culture medium containing heavy water with a certain concentration and corresponding drug concentration for culturing for a period of time, then collecting the Raman spectrum of the single cell, and evaluating the action effect of the drug at the single cell level according to the action principle of different drugs on bacterial cells and the difference of Raman heavy water peak morphological areas generated by different effects. The method has the advantages of simple operation, less sample consumption, relatively short time and low cost, and the living single-cell Raman spectrum technology adopted by the method can be combined with the heavy water labeling technology to evaluate and screen the drugs which cause different metabolic inhibition degrees on the target cells, and can evaluate the drug action level on a time axis span, so the method has universality in the fields of bacteria, mammalian cells and the like and has wide application prospect.
In the following examples, unless otherwise specified, all methods used are conventional and all reagents used are commercially available.
Example 1 evaluation of the Effect of sodium fluoride (NaF) on S.mutans UA159 by the deuterium-Raman technique
NaF is a common mouthwash and toothpaste additive, and has a remarkable effect on preventing oral diseases such as dental caries. S. mutans UA159 has a MIC of 0.4g/L for NaF.
1) Cell culture
S. mutans UA159 strain was streaked from-80 ℃ and anaerobically cultured at 37 ℃ for about 36 hours; then selecting a single clone to be transferred into 5-10ml of BHI liquid culture medium, standing and activating at 37 ℃ overnight;
inoculating 20mL of strain containing D into the strain after the activated strain is centrifuged according to the inoculation amount of 1:10 in volume ratio2O and BHI liquid culture medium with different NaF concentrations, and anaerobic static culture at 37 ℃. The different concentrations of NaF are 0,0.2,0.4,0.6,1.2g/L NaF, D2The O concentration was 30%.
2) Raman measurement
Respectively taking 500 μ L of the above D-containing solution at different time periods of 0,0.5,1,1.5,2,3,4,6 and 8h2O and NaF at various concentrations, with ddH2O washing for 3 times, centrifugal speedAt 2500 Xg, centrifuge for 3min, use ddH of the same volume2O heavy suspension and corresponding dilution are carried out to make the final concentration of the cells reach 106and/mL. Spotting 1.5. mu.L of the dilution onto CaF2And (5) drying on a glass slide.
Observing the air-dried sample under a Raman microscope, positioning a laser point to a cell to be detected, and then carrying out Raman spectrum collection. The laser wavelength is 532nm, the laser intensity on the sample is about 1-100mW, and the collection time of the Raman spectrum is 0.01-100 s. Each concentration was set up with 3 biological replicates, each replicate taking 20 cell profiles at each time point (see figure 1).
3) Data processing
And carrying out background removal, baseline normalization and maximum value standardization processing on the collected Raman spectrum by using LabSpec software.
After treatment, the obvious C-D peak appears in the SCRS under the condition of the existence of heavy water, and the C-D peak (1800 + 2500 cm) is obtained at the same time-1) Area, and then calculate C-D-ratio, and Δ C-D-ratio.
Wherein the C-D-ratio is defined by a C-D peak (1800--1) Area divided by C-D peak (1800--1) And C-H peak (2600--1) And calculating the sum of the areas. Δ C-D-ratio is obtained by subtracting the average value of C-D-ratio of 0h from C-D-ratio of each time point.
As can be seen from the above, the SCRS has obvious C-D peak, and the saturated C-D ratio is different with the heavy water concentration, and the two are in linear correlation relationship.
According to the above experimental results, the present invention proposes a new drug concentration use guide standard MIC-MA, i.e. "minimum inhibitory metabolic concentration". This new index is defined as the minimum drug concentration at which the median Δ C-D-ratio of the cells is below 0 after 8h drug exposure.
FIG. 1 shows the change in C-D-ratio of cells treated with different concentrations of NaF. All of the C-D peaks of cells exposed to NaF increased slowly compared to the control without NaF, and most of the saturated C-D-ratio was lower than the control (except for 0.2g/L NaF). Furthermore, as the NaF concentration increases, the increase in C-D-ratio is regularly delayed and the saturated C-D-ratio value gradually decreases. At 0.2g/L NaF below the MIC, the increase in C-D-ratio slowed, but the final saturated C-D-ratio value still rose to the same level as the control; at 0.4g/L NaF, which is equal to the MIC, a significant lag phase in the increase in C-D-ratio occurred, but there was still an increase in the late phase, demonstrating that under the conditions in which cell growth was inhibited, its activity was not completely inhibited; above MIC, the lag phase was longer (0.6g/L NaF) or the C-D-ratio did not increase (1.2g/L NaF) all the time, demonstrating that the cell activity was completely inhibited.
From the results of the Δ C-D-ratio calculation at 8h, the MIC-MA of S.mutans UA159 to NaF was judged to be 1.2g/L (FIG. 2). This concentration is much higher than its MIC value (0.4 g/L). At MIC concentrations, although cells do not grow significantly, their metabolic activity is not completely inhibited, and thus the pathogenic bacteria will reactivate and cause disease recurrence after removal of the drug. The risk is greatly reduced by the use of drugs under MIC-MA conditions.
Example 2 evaluation of the Effect of Chlorhexidine (CHX) on S.mutans UA159 Using the deuterium-Raman technique
Chlorhexidine is a common mouthwash additive, is a spectral bactericide, and can interfere the formation of bacterial plaque and reduce cell adsorption, thereby achieving the purpose of preventing and reducing periodontal diseases and dental caries. S. mutans UA159 has a MIC of 2mg/L for CHX.
1) Cell culture
S. mutans UA159 strain was streaked from-80 ℃ and anaerobically cultured at 37 ℃ for about 36 hours; then selecting a single clone to be transferred into 5-10ml of BHI liquid culture medium, standing and activating at 37 ℃ overnight;
inoculating 20mL of strain containing D into the strain after the activated strain is centrifuged according to the inoculation amount of 1:10 in volume ratio2O and BHI liquid culture medium with different CHX concentrations, and anaerobic static culture at 37 ℃. The different concentrations of CHX are 0,1.2,2,4mg/L CHX, D2The O concentration was 30%.
2) The Raman measurement is carried out by taking 500 μ L of the above D-containing substance at different times of 0,0.5,1,1.5,2,3,4,6 and 8h2O and CHX at various concentrations, with ddH2Washing with O for 3 times at 2500 Xg for 3min, and washing with ddH of the same volume2O heavy suspension and corresponding dilution are carried out to make the final concentration of the cells reach 106and/mL. Taking 1.5. mu.L of diluent and adding into CaF2And (5) drying on a glass slide.
Observing the air-dried sample under a Raman microscope, positioning a laser point to a cell to be detected, and then carrying out Raman spectrum collection. The laser wavelength is 532nm, the laser intensity on the sample is about 1-100mW, and the collection time of the Raman spectrum is 0.01-100 s. Each concentration was set up with 3 biological replicates, each replicate taking 20 cell profiles at each time point (see figure 1).
3) Data processing
And carrying out background removal, baseline normalization and maximum value standardization processing on the collected Raman spectrum by using LabSpec software.
After treatment, the obvious C-D peak appears in the SCRS under the condition of the existence of heavy water, and the C-D peak (1800 + 2500 cm) is obtained at the same time-1) Area, and then calculate C-D-ratio, and Δ C-D-ratio.
Wherein the C-D-ratio is defined by a C-D peak (1800--1) Area divided by C-D peak (1800--1) And C-H peak (2600--1) And calculating the sum of the areas. Δ C-D-ratio is obtained by subtracting the average value of C-D-ratio of 0h from C-D-ratio of each time point.
As can be seen from the above, the SCRS has obvious C-D peak, and the saturated C-D ratio is different with the heavy water concentration, and the two are in linear correlation relationship.
According to the above experimental results, the present invention proposes a new drug concentration use guide standard MIC-MA, i.e. "minimum inhibitory metabolic concentration". This new index is defined as the minimum drug concentration at which the median Δ C-D-ratio of the cells is below 0 after 8h drug exposure.
FIG. 3 shows the change in C-D-ratio of cells after different concentrations of CHX treatment. All of the cells exposed to CHX showed a slower increase in the C-D peak and a lower saturation C-D-ratio than the control, compared to the control without CHX. Furthermore, as CHX concentration increases, the increase in C-D-ratio is regularly delayed and the saturated C-D-ratio value gradually decreases. At 1.2mg/L CHX below the MIC, the C-D-ratio increased relatively slowly and the final saturated C-D-ratio value was about 84% of the control level; at 2mg/L CHX, which is equal to MIC, there was a significant lag phase in the increase in C-D-ratio, but there was still an increase in the later phase, demonstrating that under the conditions in which cell growth was inhibited, its activity was not completely inhibited; the C-D-ratio was never increased above the MIC condition, i.e., 4mg/L CHX, demonstrating that cellular activity was completely inhibited.
From the calculation of Δ C-D-ratio at 8h, the MIC-MA of S.mutans UA159 to CHX was judged to be 4mg/L (FIG. 4). This concentration is much higher than its MIC value (2 mg/L). At MIC concentrations, although cells do not grow significantly, their metabolic activity is not completely inhibited, and thus the pathogenic bacteria will reactivate and cause disease recurrence after removal of the drug. The risk is greatly reduced by the use of drugs under MIC-MA conditions.
Example 3 evaluation of the Effect of ampicillin (Amp) on S.mutans UA159 by the deuterium-Raman technique
Ampicillin is a commonly used antibiotic and can treat oral inflammation. S. mutans UA159 has a MIC of 0.8mg/L for Amp.
1) Cell culture
S. mutans UA159 strain was streaked from-80 ℃ and anaerobically cultured at 37 ℃ for about 36 hours; then selecting a single clone to be transferred into 5-10ml of BHI liquid culture medium, standing overnight at 37 ℃ for activation;
inoculating 20mL of strain containing D into the strain after the activated strain is centrifuged according to the inoculation amount of 1:10 in volume ratio2O and BHI liquid culture medium with different concentrations of Amp, and anaerobic static culture at 37 ℃. The different concentrations of Amp are 0,0.4,0.8,1.6,4,50mg/L Amp, D2The O concentration was 30%.
2) Raman measurement
Respectively taking 500 μ L of the above D-containing solution at different time periods of 0,0.5,1,1.5,2,3,4,6 and 8h2O and Amp at different concentrations, with ddH2Washing with O for 3 times at 2500 Xg for 3min, and washing with ddH of the same volume2O heavy suspension and corresponding dilution are carried out to make the final concentration of the cells reach 106and/mL. Spotting 1.5. mu.L of the dilution onto CaF2And (5) drying on a glass slide.
Observing the air-dried sample under a Raman microscope, positioning a laser point to a cell to be detected, and then carrying out Raman spectrum collection. The laser wavelength is 532nm, the laser intensity on the sample is about 1-100mW, and the collection time of the Raman spectrum is 0.01-100 s. Each concentration was set up with 3 biological replicates, each replicate taking 20 cell profiles at each time point (see figure 1).
3) Data processing
And carrying out background removal, baseline normalization and maximum value standardization processing on the collected Raman spectrum by using LabSpec software.
After treatment, the obvious C-D peak appears in the SCRS under the condition of the existence of heavy water, and the C-D peak (1800 + 2500 cm) is obtained at the same time-1) Area, and then calculate C-D-ratio, and Δ C-D-ratio.
Wherein the C-D-ratio is defined by a C-D peak (1800--1) Area divided by C-D peak (1800--1) And C-H peak (2600--1) And calculating the sum of the areas. Δ C-D-ratio is obtained by subtracting the average value of C-D-ratio of 0h from C-D-ratio of each time point.
As can be seen from the above, the SCRS has obvious C-D peak, and the saturated C-D ratio is different with the heavy water concentration, and the two are in linear correlation relationship.
According to the above experimental results, the present invention proposes a new drug concentration use guide standard MIC-MA, i.e. "minimum inhibitory metabolic concentration". This new index is defined as the minimum drug concentration at which the median Δ C-D-ratio of the cells is below 0 after 8h drug exposure.
FIG. 5 shows the change in C-D-ratio of cells treated with different concentrations of Amp. All cells exposed to ampicillin showed a slower increase in the C-D peak and a lower saturation of C-D-ratio than the control without Amp. Furthermore, as ampicillin concentration increased, the increase in C-D-ratio was substantially regularly delayed and the saturated C-D-ratio value gradually decreased (except for 0.4mg/L Amp). At 0.4mg/L Amp below the MIC, the C-D-ratio increases relatively slowly; equal to MIC, i.e., 0.8mg/L Amp, the final saturation C-D-ratio value was about 83% of the control level, demonstrating that the activity was not completely inhibited under conditions in which cell growth was inhibited; the C-D-ratio also increased significantly above the MIC, and even at 60-fold MIC (50mg/L Amp), the final saturated C-D-ratio reached 51% of the control level. At all concentrations, a significant increase in the C-D peak was observed at 0.5h, with no lag phase present, demonstrating that cell activity was not completely inhibited under all conditions tested. The reason for this is presumed to be that Amp acts by inhibiting the transpeptidase activity of cells, thereby affecting the synthesis of cell walls during division to make them unable to divide, but does not absolutely inhibit the activity of living cells.
From the Δ C-D-ratio calculation at 8h, it was judged that S.mutans UA159 could not find MIC-MA at the tested concentration for Amp (FIG. 6). At or above the MIC tested, the cells did not grow but retained a level of metabolic activity all the time, and therefore their bactericidal effect was left to be tested further.
Example 4 evaluation of different resistance of S.mutans UA159 and S.mutans C180-2FR to NaF Using the deuterium-Raman technique
S. mutans C180-2FR is a NaF-tolerant bacterium with a MIC for NaF of 1.6g/L, which is much higher than 0.4g/L for S.mutans UA 159. The existence of the bacteria can cause that the addition of NaF with low concentration has no obvious bactericidal and bacteriostatic effects. Therefore, the method for screening the drug-resistant bacteria in the environment also has important clinical significance.
1) Cell culture
Streaking S.mutans UA159 and S.mutans C180-2FR strains from-80 deg.C, and anaerobically culturing at 37 deg.C for about 36 h; then respectively selecting monoclonals to be transferred into 5-10ml of BHI liquid culture medium, and standing overnight at 37 ℃ for activation;
inoculating 20mL of activated S.mutans UA159 strain into the strain containing D according to the inoculation amount of 1:10 in volume ratio after centrifugation2O and BHI liquid culture medium with different NaF concentrations, and anaerobic static culture at 37 ℃. The different concentrations of NaF are 0,0.4,1.2g/L NaF, D2The O concentration was 30%.
Inoculating 20mL of the activated S.mutans C180-2FR strain into the strain containing D according to the inoculation amount of 1:10 in volume ratio after centrifugation2O and BHI liquid culture medium with different NaF concentrations, and anaerobic static culture at 37 ℃. The different concentrations of NaF are 0,0.4,1.6g/L NaF, D2The O concentration was 30%.
2) Raman measurement
Respectively taking 500 μ L of the above D-containing substances at different time periods of 0,0.5,1,1.5,2,3,4,6 and 8h2Of O and NaF in different concentrationsCulture solution using ddH2Washing with O for 3 times at 2500 Xg for 3min, and washing with ddH of the same volume2O heavy suspension and corresponding dilution are carried out to make the final concentration of the cells reach 106and/mL. Spotting 1.5. mu.L of the dilution onto CaF2And (5) drying on a glass slide.
Observing the air-dried sample under a Raman microscope, positioning a laser point to a cell to be detected, and then carrying out Raman spectrum collection. The laser wavelength is 532nm, the laser intensity on the sample is about 1-100mW, and the collection time of the Raman spectrum is 0.01-100 s. Each concentration was set up with 3 biological replicates, each replicate taking 20 cell profiles at each time point (see figure 1).
3) Data processing
And carrying out background removal, baseline normalization and maximum value standardization processing on the collected Raman spectrum by using LabSpec software.
After treatment, the obvious C-D peak appears in the SCRS under the condition of the existence of heavy water, and the C-D peak (1800 + 2500 cm) is obtained at the same time-1) Area, and then calculate C-D-ratio, and Δ C-D-ratio.
Wherein the C-D-ratio is defined by a C-D peak (1800--1) Area divided by C-D peak (1800--1) And C-H peak (2600--1) And calculating the sum of the areas. Δ C-D-ratio is obtained by subtracting the average value of C-D-ratio of 0h from C-D-ratio of each time point.
As can be seen from the above, the SCRS has obvious C-D peak, and the saturated C-D ratio is different with the heavy water concentration, and the two are in linear correlation relationship.
According to the above experimental results, the present invention proposes a new drug concentration use guide standard MIC-MA, i.e. "minimum inhibitory metabolic concentration". This new index is defined as the minimum drug concentration at which the median Δ C-D-ratio of the cells is below 0 after 8h drug exposure.
FIG. 7 shows the different change patterns of C-D-ratio of two cells after treatment with NaF at different concentrations. In the absence of NaF, the C-D-ratio of C180-2FR was lower than UA159 for the first 3h and leveled off after 4 h. This phenomenon is mainly caused by the slightly slower growth rate of C180-2FR compared to UA 159. Whereas at 0.4g/L NaF (MIC of UA159), the increase in C-D-ratio of UA159 showed a significant lag phase, beginning to climb after 2h, with the saturated C-D-ratio value remaining at the level of 44% of the control; whereas the increase in C-D-ratio of C180-2FR was essentially unaffected. Under 1.2g/L NaF, the C-D-ratio of UA159 is not increased at all, and the metabolic activity is completely inhibited; on the other hand, even in the presence of 1.6g/L NaF (MIC of C180-2 FR), the increase in C-D-ratio of C180-2FR climbed slowly after a lag of 0.5h had occurred, eventually remaining at a level corresponding to 62% of the control. Therefore, drug-resistant bacteria and drug-sensitive bacteria can be rapidly distinguished and identified by using a deuterium-Raman technology and comparing the metabolic activity change trends of different bacteria under the same drug action.
The application embodiment of the invention adopts common oral microorganisms as a mode system, but the heavy water can be metabolized and utilized by most microorganisms and can be detected by a Raman technology, namely the heavy water-Raman technology has universality among different microorganisms, and the application of the technology can be extended to different human bodies and even environmental microorganisms, even human bodies and mammalian cells.
Claims (6)
1. A method for rapidly qualitatively/quantitatively evaluating the action effects of different antibacterial drugs is characterized in that: and (3) culturing the anti-bacteria by using the heavy water marker and the drug to be detected, respectively acquiring single-cell Raman spectra at different time points in a culture period, generating Raman spectra of C-D peaks with different heights due to different metabolic activities of cells under different drugs to be detected and different concentrations of the drugs to be detected, and judging the sensitivity of the drug to be detected according to the Raman spectra.
2. The method of claim 1, wherein: adding the anti-bacteria into different drugs to be detected, comparing the generation speed of the C-D peak of the cell under different drugs to be detected with a control without the drugs, and judging the sensitivity to the drugs.
3. The method of claim 1, wherein: the method detects the C-D peak (1800--1) Change by the C-D peak (1800--1) Obtaining the C-D-ratio of the single cell by variation calculation; and obtaining the delta C-D-ratio at different time points by the C-D-ratio, further obtaining the minimum inhibitory metabolic concentration MIC-MA of the drug to be detected, namely quantitatively judging the sensitivity of the drug to be detected.
4. The method of claim 3, wherein: the C-D-ratio is C-D/(C-D + C-H), wherein C-D is a C-D peak (1800 ion 2500 cm)-1) Area, C-H is C-H peak (2600-3300 cm)-1) Area; the Δ C-D-ratio is subtracted from the average of 0h of C-D-ratio over each time point; the minimum inhibitory metabolic concentration MIC-MA is the minimum drug concentration at which the median Δ C-D-ratio of the cells is below 0 after several hours of drug exposure.
5. The method of claim 4, wherein: and (3) culturing the disease-resistant bacteria in the stage of culturing to a culture medium containing heavy water and the drug to be detected with different concentrations, and respectively acquiring the single-cell Raman spectra of the culture solution cells at different time points in the culture period, wherein the time for acquiring the Raman spectra is 0.01-100s under the laser with the energy of 1-100 mW.
6. The method of claim 5, wherein: the different concentrations of the drug to be detected are gradients from below the minimum inhibitory concentration to above the minimum inhibitory concentration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010815660.0A CN112014372A (en) | 2017-02-20 | 2017-02-20 | Method for quickly, qualitatively and quantitatively evaluating action effects of different antibacterial drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010815660.0A CN112014372A (en) | 2017-02-20 | 2017-02-20 | Method for quickly, qualitatively and quantitatively evaluating action effects of different antibacterial drugs |
CN201710089193.6A CN108459001B (en) | 2017-02-20 | 2017-02-20 | Method for rapidly and quantitatively evaluating action effects of different antibacterial drugs |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710089193.6A Division CN108459001B (en) | 2017-02-20 | 2017-02-20 | Method for rapidly and quantitatively evaluating action effects of different antibacterial drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112014372A true CN112014372A (en) | 2020-12-01 |
Family
ID=63221950
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010815660.0A Pending CN112014372A (en) | 2017-02-20 | 2017-02-20 | Method for quickly, qualitatively and quantitatively evaluating action effects of different antibacterial drugs |
CN201710089193.6A Active CN108459001B (en) | 2017-02-20 | 2017-02-20 | Method for rapidly and quantitatively evaluating action effects of different antibacterial drugs |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710089193.6A Active CN108459001B (en) | 2017-02-20 | 2017-02-20 | Method for rapidly and quantitatively evaluating action effects of different antibacterial drugs |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN112014372A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113974618A (en) * | 2021-12-12 | 2022-01-28 | 广西澍源智能科技有限公司 | Noninvasive blood glucose testing method based on water peak blood glucose correction |
US11358984B2 (en) | 2018-08-27 | 2022-06-14 | Regeneran Pharmaceuticals, Inc. | Use of Raman spectroscopy in downstream purification |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112080545A (en) * | 2019-06-14 | 2020-12-15 | 中国科学院青岛生物能源与过程研究所 | Single-cell Raman clinical drug resistance kit and detection method |
CN110643675A (en) * | 2019-10-31 | 2020-01-03 | 上海氘峰医疗器械有限公司 | Method for rapidly detecting drug resistance of bacteria |
CN113736847B (en) * | 2020-05-28 | 2024-04-02 | 中国科学院青岛生物能源与过程研究所 | Kit and method for rapidly detecting drug resistance of helicobacter pylori |
CN113740310A (en) * | 2020-05-29 | 2021-12-03 | 中国科学院青岛生物能源与过程研究所 | Method for screening or evaluating drugs |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60233060D1 (en) * | 2001-09-06 | 2009-09-03 | Genomic Profiling Systems Inc | QUICK REFERENCE OF REPLICATING CELLS |
US20050186679A1 (en) * | 2004-02-24 | 2005-08-25 | Christian Viskov | Method for determining specific groups constituting heparins or low molecular weight heparins |
TWI409077B (en) * | 2006-04-18 | 2013-09-21 | Piramal Life Sciences Ltd | Novel antibacterial compounds |
CN101308084A (en) * | 2007-05-16 | 2008-11-19 | 中国科学院半导体研究所 | Method for discriminating sample for containing tiny semiconductor carbon nanometer tube bundle or not |
JP6322888B2 (en) * | 2013-01-15 | 2018-05-16 | 株式会社ソシオネクスト | Semiconductor test program, semiconductor test apparatus, and semiconductor test method |
US9562010B2 (en) * | 2013-01-22 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Cross-linking compositions and related methods of isotope tagging of interacting proteins and analysis of protein interactions |
-
2017
- 2017-02-20 CN CN202010815660.0A patent/CN112014372A/en active Pending
- 2017-02-20 CN CN201710089193.6A patent/CN108459001B/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11358984B2 (en) | 2018-08-27 | 2022-06-14 | Regeneran Pharmaceuticals, Inc. | Use of Raman spectroscopy in downstream purification |
CN113974618A (en) * | 2021-12-12 | 2022-01-28 | 广西澍源智能科技有限公司 | Noninvasive blood glucose testing method based on water peak blood glucose correction |
Also Published As
Publication number | Publication date |
---|---|
CN108459001A (en) | 2018-08-28 |
CN108459001B (en) | 2020-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108459001B (en) | Method for rapidly and quantitatively evaluating action effects of different antibacterial drugs | |
Grela et al. | Current methodology of MTT assay in bacteria–A review | |
Eloff | Avoiding pitfalls in determining antimicrobial activity of plant extracts and publishing the results | |
Manibalan et al. | Electrochemical latent redox ratiometric probes for real-time tracking and quantification of endogenous hydrogen sulfide production in living cells | |
US8688384B2 (en) | Automated characterization and classification of microorganisms | |
Boumba et al. | Microbial ethanol production: experimental study and multivariate evaluation | |
Pham et al. | Automated scoring of fear-related behavior using EthoVision software | |
Kairo et al. | Development of a tetrazolium salt assay for rapid determination of viability of BCG vaccines | |
Boumba et al. | Modeling microbial ethanol production by E. coli under aerobic/anaerobic conditions: applicability to real postmortem cases and to postmortem blood derived microbial cultures | |
Jayan et al. | Surface-enhanced Raman spectroscopy combined with stable isotope probing to assess the metabolic activity of Escherichia coli cells in chicken carcass wash water | |
CN102559844A (en) | Preparation method of detecting system for minimal inhibitory concentration of mycobacteria | |
AU2018235992B2 (en) | Device, method, and system for identifying organisms and determining their sensitivity to toxic substances using the changes in the concentrations of metabolites present in growth medium | |
Zhang et al. | Rapid antimicrobial susceptibility testing by stimulated Raman scattering metabolic imaging and morphological deformation of bacteria | |
Carvalho et al. | Skin microbiota and the cosmetic industry | |
Chen et al. | Effects of DJK-5 and chlorhexidine on exopolysaccharide volume and pH in oral biofilms | |
Petrenko et al. | The reduction of Alamar Blue by peripheral blood lymphocytes and isolated mitochondria | |
Tapsall | Pigment production by Lancefield-group-B streptococci (Streptococcus agalactiae) | |
Mihailescu et al. | Nicotine stimulation of dorsal raphe neurons: effects on laterodorsal and pedunculopontine neurons | |
CN110669820A (en) | Quick detection method for microbial drug sensitivity | |
US9625479B1 (en) | Automated preservative efficacy test method and device | |
Taylor et al. | Modelling the effects of pH on tongue biofilm using a sorbarod biofilm perfusion system | |
CN104622871B (en) | A kind of oxazolone compounds is as the application of Streptococcus mutans bioflm inhibiting agents | |
Teanpaisan et al. | Production and sensitivity of bacteriocin-like activity among Porphyromonas gingivalis, Prevotella intermedia and Pr. nigrescens strains isolated from periodontal sites | |
KR20210122704A (en) | Method for pathogen detection | |
Yokoyama et al. | Hydrogen peroxide augmentation in a rat striatum after methamphetamine injection as monitored in vivo by a Pt-disk microelectrode |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201201 |
|
WD01 | Invention patent application deemed withdrawn after publication |